SlideShare uma empresa Scribd logo
1 de 112
Baixar para ler offline
Neoplasia 4,[object Object],Fe A. Bartolome, MD, FPASMAP,[object Object],Department of Pathology,[object Object],Our Lady of Fatima University,[object Object]
Chemical ,[object Object],Carcinogenesis,[object Object]
Neoplasia 4
Chemical ,[object Object],Carcinogenesis,[object Object],[object Object]
Initiation alone is not sufficient for tumor formation.
Initiation causes permanent DNA damage (mutations). It is rapid and irreversible  and has  “memory.”,[object Object]
For the change to be heritable, the damaged DNA template must be replicated
For initiation to occur, altered cells must undergo at least one cycle of proliferation so that DNA change becomes fixed,[object Object]
Tumors do not result when the promoting agent is applied before, rather than after, the initiating agent.
The cellular changes resulting from application of promoters do not affect DNA directly and are reversible.,[object Object]
Mutated cells with reduced growth factor requirements
Process of tumor promotion includes multiple steps: proliferation of pre-neoplastic cells, malignant conversion, and tumor progression,[object Object]
Neoplasia 4
Chemical Carcinogenesis: Initiators,[object Object],Direct-Acting Agents,[object Object],[object Object]
Most are weak carcinogens; some are chemotherapeutic drugs (e.g. Alkylating drugs)
Risk of induced cancer is low.,[object Object]
Chemical Carcinogenesis: Initiators,[object Object],Indirect-Acting Agents,[object Object],[object Object]
Polycyclic hydrocarbons
present in fossil fuels; animal fats during process of broiling meats; smoked meat and fish
Principal active product: epoxides form adducts with DNA, RNA, and proteins,[object Object]
Example: benzo[a]pyrene light smokers with the susceptible genotype CYP1A1 with 7x higher risk of developing lung cancer,[object Object]
Any gene may be the target  commonly mutated are RAS and p53
Aflatoxin B1  cause G:C  T:A transversion in codon 249 of p53,[object Object]
Degree of risk depends on:Type of UV ray,[object Object],Intensity of exposure,[object Object],Quantity of light-absorbing protective coat of melanin,[object Object]
Neoplasia 4
UVB radiation is the main cause of sunburn and skin cancer although mounting evidence suggests UVA may also play a role. UVB does not penetrate the skin as deeply as UVA but has more energy and therefore does more damage to the skin. ,[object Object]
UVB sunlight is directly absorbed by DNA resulting in single strand breaks and the formation of pyrimidinedimers. ,[object Object]
Neoplasia 4
Neoplasia 4
Radiation Carcinogenesis,[object Object],Ionizing Radiation,[object Object],[object Object]
Lead to formation of reactive oxygen species or free radicals,[object Object]
Intermediate: breast, lungs, salivary glands
Resistant: skin, bone, GIT,[object Object]
Neoplasia 4
Neoplasia 4
Microbial Carcinogenesis,[object Object]
Microbial Carcinogenesis,[object Object]
Neoplasia 4
Microbial Carcinogenesis,[object Object],Oncogenic RNA Viruses: HTLV type 1,[object Object],[object Object]
Does not contain an oncogene
Viral integration shows clonal pattern  site of integration identical within all cells of a given cancer,[object Object]
Genes encoding IL-2 & its receptor
Gene for myeloid growth factor granulocyte-macrophage colony-stimulating factor,[object Object]
Neoplasia 4
Neoplasia 4
Microbial Carcinogenesis,[object Object],OncogenicDNAViruses: HPV,[object Object],[object Object]
HPV genome integrated into host genome  site of integration random but pattern of integration is clonal,[object Object]
Microbial Carcinogenesis,[object Object],OncogenicDNAViruses: HPV,[object Object],[object Object],[object Object]
Neoplasia 4
Microbial Carcinogenesis,[object Object],OncogenicDNAViruses: EBV,[object Object],[object Object]
Infects B cells and possibly epithelial cells of the oropharynx via complement receptor CD21,[object Object]
Involves the “hijacking” of several normal signalling pathways,[object Object]
Microbial Carcinogenesis,[object Object],OncogenicDNAViruses: EBV,[object Object],[object Object],Encodes a nuclear protein that mimics a constitutively active Notch receptor,[object Object],Transactivates several host genes  cyclin D and src family of proto-oncogenes,[object Object]
Microbial Carcinogenesis,[object Object],OncogenicDNAViruses: EBV,[object Object],[object Object]
Impair immune competence  allow sustained B-cell proliferation
Cause translocations that activate c-MYC oncogene,[object Object]
No consistent pattern of integration in liver cells
Immunologically-mediated chronic inflammation with hepatocyte death  regeneration and genomic damage,[object Object]
Neoplasia 4
Neoplasia 4
Neoplasia 4
Microbial Carcinogenesis,[object Object],Helicobacter pylori,[object Object],[object Object]
Implicated in gastric adenocarcinoma and gastric lymphomas
Involves increased epithelial cell proliferation in a background of chronic inflammation  contain genotoxic agents such as ROS,[object Object]
Penetrates into gastric epithelial cells  initiate signalling cascade that mimics unregulated growth factor stimulation
Additional mutations may be acquired (e.g. (11:18) translocation)  cause constitutive activation of NF-κβ,[object Object]
Neoplasia 4
Neoplasia 4
Tumor Immunity,[object Object],Immune surveillance,[object Object],[object Object]
(+) lymphocytic infiltrates around tumors and in LN draining sites of cancer
Increased incidence of cancer in immunocompromised individuals
Demonstration of tumor-specific T cells and antibodies,[object Object]
Initially classified as:Tumor-specific antigens,[object Object],[object Object],Tumor-associated antigens,[object Object],[object Object],[object Object]
Not present in normal cells  do not induce self-tolerance,[object Object],[object Object],[object Object]
Genes silenced during development and activated during malignant transformation,[object Object]
Tumor Immunity,[object Object],Tumor antigens,[object Object],Altered cell surface glycolipids and glycoproteins,[object Object],[object Object]
Melanomas: high levels of gangliosides GM2, GD2, and GD3
Target for cancer therapy with specific antibodies,[object Object]
Cancer cells entering the bloodstream form complex thromboemboli with platelets and leukocytes, which are thought to facilitate arrest at ectopic sites, assist interactions with the endothelium, and help in evasion of the immune system. Current data suggest that this phenomenon can be explained by interactions between platelet and/or endothelial P-selectin and carcinoma mucins. ,[object Object]
Tumor Immunity,[object Object],Tumor antigens,[object Object],Cell type-specific differentiation antigens,[object Object],[object Object]
Typically normal self-antigens  do not induce immune response
Potential targets for immunotherapy and for identifying the tissue of origin of tumors,[object Object]
Neoplasia 4
Tumor Immunity,[object Object],Anti-tumorEffector Mechanisms,[object Object],Cytotoxic T lymphocytes,[object Object],[object Object]
Demonstrated in blood and tumor infiltrates of cancer patients,[object Object]
Tumor Immunity,[object Object],Anti-tumorEffector Mechanisms,[object Object],Natural killer cells,[object Object],[object Object]
Activated by IL-2 and IL-5; may be activated by tumors that fail to express MHC class I antigens
NKG2D proteins  activating receptors; recognize stress-induced antigens expressed on tumor cells,[object Object]
Tumor Immunity,[object Object],Anti-tumorEffector Mechanisms,[object Object],Macrophages ,[object Object],[object Object]
Kill tumors by mechanisms similar to those used to kill microbes or by secretion of TNF,[object Object]
Tumor Immunity,[object Object],Anti-tumorEffector Mechanisms,[object Object],Antibodies ,[object Object],[object Object]
Monoclonal antibody vs. CD20 (B-cell surface antigen)  treatment of lymphomas,[object Object],[object Object],[object Object]
Express arginase arginine essential component of TCR  loss of T cell recognition,[object Object]
Immune response induced by the tumor may inhibit tumor immunity by activation of T-cell inhibitory receptor CTLA4,[object Object],[object Object],[object Object],[object Object]
Neoplasia 4
Clinical Aspects of Neoplasia,[object Object],[object Object],Location and impingement on adjacent structures,[object Object],Functional activity (e.g. Hormone synthesis or development of para-neoplastic syndrome),[object Object],Bleeding and infections due to ulceration of tumor through adjacent surfaces,[object Object],Symptoms due to rupture or infarction,[object Object],Cachexia or wasting,[object Object]
Clinical Aspects of Neoplasia,[object Object],Local and Hormonal Effects,[object Object],[object Object]
Hormone production seen in neoplasms arising in endocrine glands  more typical of benign tumor
Neoplasms in the gut  obstruction or intussusception,[object Object]
Melena and hematuria characteristic of neoplasms of the gut and urinary tract,[object Object],[object Object]
Clinical Aspects of Neoplasia,[object Object],Paraneoplastic Syndromes,[object Object],Endocrinopathies,[object Object],[object Object]
Cushing syndrome – most common endocrinopathy 50% with small cell CA of lungs; due to excessive corticotropin production,[object Object]
Two processes involved:Osteolysis induced by cancer,[object Object],Production of calcemichumoral substances in extra-osseous neoplasms,[object Object]
Clinical Aspects of Neoplasia,[object Object],Paraneoplastic Syndromes,[object Object],Acanthosisnigricans,[object Object],[object Object]
Genetically determined; juveniles or adults,[object Object]
Clinical Aspects of Neoplasia,[object Object],Cancer Cachexia,[object Object],[object Object]
Weight loss results equally from loss of fat and lean muscle
Due to increased basal metabolic rate despite reduced food intake,[object Object]
Grading and Staging,[object Object],Cancer Grading,[object Object],[object Object]
Provides information about potential behavior of tumor
Of less clinical value than staging,[object Object]
Neoplasia 4

Mais conteúdo relacionado

Mais procurados

Tumors of Epithelial Tissue
Tumors of Epithelial TissueTumors of Epithelial Tissue
Tumors of Epithelial TissueGunJee Gj
 
Cancer invasion and metastasis
Cancer invasion and metastasisCancer invasion and metastasis
Cancer invasion and metastasisNilesh Kucha
 
Cell injury : Intracellular accumulations
Cell injury : Intracellular accumulationsCell injury : Intracellular accumulations
Cell injury : Intracellular accumulationsVijay Shankar
 
Molecular basis of metastasis
Molecular basis of metastasisMolecular basis of metastasis
Molecular basis of metastasismeducationdotnet
 
Intracellular accumulations and calcifications 22 9-2016
Intracellular accumulations and calcifications 22 9-2016Intracellular accumulations and calcifications 22 9-2016
Intracellular accumulations and calcifications 22 9-2016pathologydept
 
Neoplasia Robbin's path
Neoplasia Robbin's pathNeoplasia Robbin's path
Neoplasia Robbin's pathPrasad CSBR
 
SPLENIC INFARCT, CVC SPLEEN & LUNGS PATHOLOGY PRACTICAL CLASS FOR MBBS
SPLENIC INFARCT, CVC SPLEEN & LUNGS PATHOLOGY PRACTICAL CLASS FOR MBBSSPLENIC INFARCT, CVC SPLEEN & LUNGS PATHOLOGY PRACTICAL CLASS FOR MBBS
SPLENIC INFARCT, CVC SPLEEN & LUNGS PATHOLOGY PRACTICAL CLASS FOR MBBSmeenuev
 
Neoplasia Characteristics and classification of cancer
Neoplasia Characteristics and classification of cancerNeoplasia Characteristics and classification of cancer
Neoplasia Characteristics and classification of cancerSubramani Parasuraman
 

Mais procurados (20)

Metastasis
MetastasisMetastasis
Metastasis
 
Acute inflammation
Acute inflammationAcute inflammation
Acute inflammation
 
Cancer - Molecular basis
Cancer - Molecular basisCancer - Molecular basis
Cancer - Molecular basis
 
Pathology practical
Pathology  practicalPathology  practical
Pathology practical
 
Tumors of Epithelial Tissue
Tumors of Epithelial TissueTumors of Epithelial Tissue
Tumors of Epithelial Tissue
 
Cancer invasion and metastasis
Cancer invasion and metastasisCancer invasion and metastasis
Cancer invasion and metastasis
 
Hemodynamic disorders
Hemodynamic disorders Hemodynamic disorders
Hemodynamic disorders
 
Carcinogens
Carcinogens  Carcinogens
Carcinogens
 
Cell injury : Intracellular accumulations
Cell injury : Intracellular accumulationsCell injury : Intracellular accumulations
Cell injury : Intracellular accumulations
 
Neoplasia 2
Neoplasia 2Neoplasia 2
Neoplasia 2
 
Carcinogenesis
CarcinogenesisCarcinogenesis
Carcinogenesis
 
Tumours
TumoursTumours
Tumours
 
Soft tissue tumor
Soft tissue tumorSoft tissue tumor
Soft tissue tumor
 
Molecular basis of metastasis
Molecular basis of metastasisMolecular basis of metastasis
Molecular basis of metastasis
 
Intracellular accumulations and calcifications 22 9-2016
Intracellular accumulations and calcifications 22 9-2016Intracellular accumulations and calcifications 22 9-2016
Intracellular accumulations and calcifications 22 9-2016
 
Neoplasiia-Epithelial tumours
Neoplasiia-Epithelial tumoursNeoplasiia-Epithelial tumours
Neoplasiia-Epithelial tumours
 
Neoplasia Robbin's path
Neoplasia Robbin's pathNeoplasia Robbin's path
Neoplasia Robbin's path
 
SPLENIC INFARCT, CVC SPLEEN & LUNGS PATHOLOGY PRACTICAL CLASS FOR MBBS
SPLENIC INFARCT, CVC SPLEEN & LUNGS PATHOLOGY PRACTICAL CLASS FOR MBBSSPLENIC INFARCT, CVC SPLEEN & LUNGS PATHOLOGY PRACTICAL CLASS FOR MBBS
SPLENIC INFARCT, CVC SPLEEN & LUNGS PATHOLOGY PRACTICAL CLASS FOR MBBS
 
carcinogens and carcinogenesis
carcinogens and carcinogenesiscarcinogens and carcinogenesis
carcinogens and carcinogenesis
 
Neoplasia Characteristics and classification of cancer
Neoplasia Characteristics and classification of cancerNeoplasia Characteristics and classification of cancer
Neoplasia Characteristics and classification of cancer
 

Semelhante a Neoplasia 4

Semelhante a Neoplasia 4 (20)

Neoplasia
NeoplasiaNeoplasia
Neoplasia
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
 
Neoplasia
NeoplasiaNeoplasia
Neoplasia
 
Neoplasia class 5.ppt
Neoplasia class 5.pptNeoplasia class 5.ppt
Neoplasia class 5.ppt
 
Carcinogenesis
CarcinogenesisCarcinogenesis
Carcinogenesis
 
Carcinogenic agents and their cellular interaction
Carcinogenic agents and their cellular interactionCarcinogenic agents and their cellular interaction
Carcinogenic agents and their cellular interaction
 
Tumor immunity
Tumor immunityTumor immunity
Tumor immunity
 
Oncogenisis and Tumor Markers
Oncogenisis and Tumor Markers Oncogenisis and Tumor Markers
Oncogenisis and Tumor Markers
 
16 CARCINOGENESIS.pptx
16 CARCINOGENESIS.pptx16 CARCINOGENESIS.pptx
16 CARCINOGENESIS.pptx
 
Cancer pathophysiology dietetics-1
Cancer pathophysiology dietetics-1Cancer pathophysiology dietetics-1
Cancer pathophysiology dietetics-1
 
Oncogenesis
OncogenesisOncogenesis
Oncogenesis
 
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
Advanced tumor immunology prof dr.ihsan edan alsaimary   university of basrah...Advanced tumor immunology prof dr.ihsan edan alsaimary   university of basrah...
Advanced tumor immunology prof dr.ihsan edan alsaimary university of basrah...
 
DNA Oncogenic Viruses
DNA Oncogenic VirusesDNA Oncogenic Viruses
DNA Oncogenic Viruses
 
Oncogenic virus-host cell interaction
Oncogenic virus-host cell interactionOncogenic virus-host cell interaction
Oncogenic virus-host cell interaction
 
Infection_ and neoplasia.pptx
Infection_ and neoplasia.pptxInfection_ and neoplasia.pptx
Infection_ and neoplasia.pptx
 
Tumor Immunology
Tumor ImmunologyTumor Immunology
Tumor Immunology
 
Tumour immunology leture notes
Tumour immunology leture notesTumour immunology leture notes
Tumour immunology leture notes
 
CANCER
CANCERCANCER
CANCER
 
Infections and cancer
Infections and cancerInfections and cancer
Infections and cancer
 
Oncogenesis AAR
Oncogenesis AAROncogenesis AAR
Oncogenesis AAR
 

Mais de MD Specialclass

Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...MD Specialclass
 
Git diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionGit diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionMD Specialclass
 
Getting ahead of headaches
Getting ahead of headachesGetting ahead of headaches
Getting ahead of headachesMD Specialclass
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL MD Specialclass
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL MD Specialclass
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinomaMD Specialclass
 
Normal sleep and sleep disorders
Normal sleep and sleep disordersNormal sleep and sleep disorders
Normal sleep and sleep disordersMD Specialclass
 
Toxic and drug induced hepatitis
Toxic and drug induced hepatitisToxic and drug induced hepatitis
Toxic and drug induced hepatitisMD Specialclass
 
Complications of cirrhosis
Complications of cirrhosisComplications of cirrhosis
Complications of cirrhosisMD Specialclass
 

Mais de MD Specialclass (20)

Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...Applied nutrition   3 rd presentation - diseases of liver, gall bladder, and ...
Applied nutrition 3 rd presentation - diseases of liver, gall bladder, and ...
 
Git diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutritionGit diseases presentn no. 2 applied nutrition
Git diseases presentn no. 2 applied nutrition
 
Getting ahead of headaches
Getting ahead of headachesGetting ahead of headaches
Getting ahead of headaches
 
Acute brain attack 911
Acute brain attack  911Acute brain attack  911
Acute brain attack 911
 
Hema intro anemia
Hema intro anemiaHema intro anemia
Hema intro anemia
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL
 
EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL EXCRETA, SEWAGE, REFUSE DISPOSAL
EXCRETA, SEWAGE, REFUSE DISPOSAL
 
Fever & id diet final
Fever & id diet finalFever & id diet final
Fever & id diet final
 
Eating disorders
Eating disordersEating disorders
Eating disorders
 
Hepatocellular carcinoma
Hepatocellular carcinomaHepatocellular carcinoma
Hepatocellular carcinoma
 
Eating disorders
Eating disordersEating disorders
Eating disorders
 
Normal sleep and sleep disorders
Normal sleep and sleep disordersNormal sleep and sleep disorders
Normal sleep and sleep disorders
 
Tic disorder
Tic disorderTic disorder
Tic disorder
 
Thyroid
ThyroidThyroid
Thyroid
 
Dermatology dr.n.ramos
Dermatology   dr.n.ramosDermatology   dr.n.ramos
Dermatology dr.n.ramos
 
Tic disorder
Tic disorderTic disorder
Tic disorder
 
Toxic and drug induced hepatitis
Toxic and drug induced hepatitisToxic and drug induced hepatitis
Toxic and drug induced hepatitis
 
Pancreatic disease
Pancreatic diseasePancreatic disease
Pancreatic disease
 
Liver disease
Liver diseaseLiver disease
Liver disease
 
Complications of cirrhosis
Complications of cirrhosisComplications of cirrhosis
Complications of cirrhosis
 

Último

UiPath Studio Web workshop series - Day 7
UiPath Studio Web workshop series - Day 7UiPath Studio Web workshop series - Day 7
UiPath Studio Web workshop series - Day 7DianaGray10
 
Building Your Own AI Instance (TBLC AI )
Building Your Own AI Instance (TBLC AI )Building Your Own AI Instance (TBLC AI )
Building Your Own AI Instance (TBLC AI )Brian Pichman
 
Bird eye's view on Camunda open source ecosystem
Bird eye's view on Camunda open source ecosystemBird eye's view on Camunda open source ecosystem
Bird eye's view on Camunda open source ecosystemAsko Soukka
 
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1DianaGray10
 
Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1DianaGray10
 
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...Aggregage
 
How Accurate are Carbon Emissions Projections?
How Accurate are Carbon Emissions Projections?How Accurate are Carbon Emissions Projections?
How Accurate are Carbon Emissions Projections?IES VE
 
Introduction to Matsuo Laboratory (ENG).pptx
Introduction to Matsuo Laboratory (ENG).pptxIntroduction to Matsuo Laboratory (ENG).pptx
Introduction to Matsuo Laboratory (ENG).pptxMatsuo Lab
 
Cybersecurity Workshop #1.pptx
Cybersecurity Workshop #1.pptxCybersecurity Workshop #1.pptx
Cybersecurity Workshop #1.pptxGDSC PJATK
 
100+ ChatGPT Prompts for SEO Optimization
100+ ChatGPT Prompts for SEO Optimization100+ ChatGPT Prompts for SEO Optimization
100+ ChatGPT Prompts for SEO Optimizationarrow10202532yuvraj
 
Crea il tuo assistente AI con lo Stregatto (open source python framework)
Crea il tuo assistente AI con lo Stregatto (open source python framework)Crea il tuo assistente AI con lo Stregatto (open source python framework)
Crea il tuo assistente AI con lo Stregatto (open source python framework)Commit University
 
UiPath Studio Web workshop series - Day 5
UiPath Studio Web workshop series - Day 5UiPath Studio Web workshop series - Day 5
UiPath Studio Web workshop series - Day 5DianaGray10
 
20230202 - Introduction to tis-py
20230202 - Introduction to tis-py20230202 - Introduction to tis-py
20230202 - Introduction to tis-pyJamie (Taka) Wang
 
ADOPTING WEB 3 FOR YOUR BUSINESS: A STEP-BY-STEP GUIDE
ADOPTING WEB 3 FOR YOUR BUSINESS: A STEP-BY-STEP GUIDEADOPTING WEB 3 FOR YOUR BUSINESS: A STEP-BY-STEP GUIDE
ADOPTING WEB 3 FOR YOUR BUSINESS: A STEP-BY-STEP GUIDELiveplex
 
UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8DianaGray10
 
IESVE Software for Florida Code Compliance Using ASHRAE 90.1-2019
IESVE Software for Florida Code Compliance Using ASHRAE 90.1-2019IESVE Software for Florida Code Compliance Using ASHRAE 90.1-2019
IESVE Software for Florida Code Compliance Using ASHRAE 90.1-2019IES VE
 
Valere | Digital Solutions & AI Transformation Portfolio | 2024
Valere | Digital Solutions & AI Transformation Portfolio | 2024Valere | Digital Solutions & AI Transformation Portfolio | 2024
Valere | Digital Solutions & AI Transformation Portfolio | 2024Alexander Turgeon
 
UiPath Community: AI for UiPath Automation Developers
UiPath Community: AI for UiPath Automation DevelopersUiPath Community: AI for UiPath Automation Developers
UiPath Community: AI for UiPath Automation DevelopersUiPathCommunity
 
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdfUiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdfDianaGray10
 
Empowering Africa's Next Generation: The AI Leadership Blueprint
Empowering Africa's Next Generation: The AI Leadership BlueprintEmpowering Africa's Next Generation: The AI Leadership Blueprint
Empowering Africa's Next Generation: The AI Leadership BlueprintMahmoud Rabie
 

Último (20)

UiPath Studio Web workshop series - Day 7
UiPath Studio Web workshop series - Day 7UiPath Studio Web workshop series - Day 7
UiPath Studio Web workshop series - Day 7
 
Building Your Own AI Instance (TBLC AI )
Building Your Own AI Instance (TBLC AI )Building Your Own AI Instance (TBLC AI )
Building Your Own AI Instance (TBLC AI )
 
Bird eye's view on Camunda open source ecosystem
Bird eye's view on Camunda open source ecosystemBird eye's view on Camunda open source ecosystem
Bird eye's view on Camunda open source ecosystem
 
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1UiPath Platform: The Backend Engine Powering Your Automation - Session 1
UiPath Platform: The Backend Engine Powering Your Automation - Session 1
 
Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1Secure your environment with UiPath and CyberArk technologies - Session 1
Secure your environment with UiPath and CyberArk technologies - Session 1
 
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
The Data Metaverse: Unpacking the Roles, Use Cases, and Tech Trends in Data a...
 
How Accurate are Carbon Emissions Projections?
How Accurate are Carbon Emissions Projections?How Accurate are Carbon Emissions Projections?
How Accurate are Carbon Emissions Projections?
 
Introduction to Matsuo Laboratory (ENG).pptx
Introduction to Matsuo Laboratory (ENG).pptxIntroduction to Matsuo Laboratory (ENG).pptx
Introduction to Matsuo Laboratory (ENG).pptx
 
Cybersecurity Workshop #1.pptx
Cybersecurity Workshop #1.pptxCybersecurity Workshop #1.pptx
Cybersecurity Workshop #1.pptx
 
100+ ChatGPT Prompts for SEO Optimization
100+ ChatGPT Prompts for SEO Optimization100+ ChatGPT Prompts for SEO Optimization
100+ ChatGPT Prompts for SEO Optimization
 
Crea il tuo assistente AI con lo Stregatto (open source python framework)
Crea il tuo assistente AI con lo Stregatto (open source python framework)Crea il tuo assistente AI con lo Stregatto (open source python framework)
Crea il tuo assistente AI con lo Stregatto (open source python framework)
 
UiPath Studio Web workshop series - Day 5
UiPath Studio Web workshop series - Day 5UiPath Studio Web workshop series - Day 5
UiPath Studio Web workshop series - Day 5
 
20230202 - Introduction to tis-py
20230202 - Introduction to tis-py20230202 - Introduction to tis-py
20230202 - Introduction to tis-py
 
ADOPTING WEB 3 FOR YOUR BUSINESS: A STEP-BY-STEP GUIDE
ADOPTING WEB 3 FOR YOUR BUSINESS: A STEP-BY-STEP GUIDEADOPTING WEB 3 FOR YOUR BUSINESS: A STEP-BY-STEP GUIDE
ADOPTING WEB 3 FOR YOUR BUSINESS: A STEP-BY-STEP GUIDE
 
UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8UiPath Studio Web workshop series - Day 8
UiPath Studio Web workshop series - Day 8
 
IESVE Software for Florida Code Compliance Using ASHRAE 90.1-2019
IESVE Software for Florida Code Compliance Using ASHRAE 90.1-2019IESVE Software for Florida Code Compliance Using ASHRAE 90.1-2019
IESVE Software for Florida Code Compliance Using ASHRAE 90.1-2019
 
Valere | Digital Solutions & AI Transformation Portfolio | 2024
Valere | Digital Solutions & AI Transformation Portfolio | 2024Valere | Digital Solutions & AI Transformation Portfolio | 2024
Valere | Digital Solutions & AI Transformation Portfolio | 2024
 
UiPath Community: AI for UiPath Automation Developers
UiPath Community: AI for UiPath Automation DevelopersUiPath Community: AI for UiPath Automation Developers
UiPath Community: AI for UiPath Automation Developers
 
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdfUiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
UiPath Solutions Management Preview - Northern CA Chapter - March 22.pdf
 
Empowering Africa's Next Generation: The AI Leadership Blueprint
Empowering Africa's Next Generation: The AI Leadership BlueprintEmpowering Africa's Next Generation: The AI Leadership Blueprint
Empowering Africa's Next Generation: The AI Leadership Blueprint
 

Neoplasia 4